NCT02388919 (ALTER0303) is a Phase 2, PHASE3 clinical trial of Anlotinib in Non-small Cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Who is sponsoring NCT02388919?

NCT02388919 is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

What drugs are being tested in NCT02388919?

Interventions in NCT02388919: Anlotinib, Placebo.

What condition does NCT02388919 study?

NCT02388919 studies Non-small Cell Lung Cancer.

Is NCT02388919 still recruiting?

NCT02388919 is currently completed. Last updated 18 September 2017.

Last reviewed 2017-09-18 · How we verify

NCT02388919: ALTER0303

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）

Completed Phase 2, PHASE3 Last updated 18 September 2017

What this trial tests

Phase 2, PHASE3 trial testing Anlotinib in Non-small Cell Lung Cancer in 439 participants. Completed in 6 January 2017.

Timeline

26 February 2015

Primary endpoint
5 January 2017

6 January 2017

Quick facts

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	439
Start date	26 February 2015
Primary completion	5 January 2017
Estimated completion	6 January 2017
Sites	40 locations across China

Drugs / interventions tested

Anlotinib — full drug profile →
Placebo

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the efficacy and safety of Anlotinib as the 3-line treatment of patients with advanced non-small lung cancer, with placebo control.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B, Li K, Wang Q, Zhang L, et al · · 2018 · cited 497× · PMID 30098152 · DOI 10.1001/jamaoncol.2018.3039
Non-small cell lung cancer in China.
Chen P, Liu Y, Wen Y, Zhou C. · · 2022 · cited 479× · PMID 36075878 · DOI 10.1002/cac2.12359
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C, Wan X, Quan H, Zheng M, et al · · 2018 · cited 273× · PMID 29446853 · DOI 10.1111/cas.13536
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.
Qin S, Li A, Yi M, Yu S, et al · · 2019 · cited 221× · PMID 30866992 · DOI 10.1186/s13045-019-0718-5
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, et al · · 2024 · cited 133× · PMID 39138146 · DOI 10.1038/s41392-024-01899-w
Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.
Liu G, Chen T, Ding Z, Wang Y, et al · · 2021 · cited 131× · PMID 33655556 · DOI 10.1111/cpr.13009
Anlotinib as a molecular targeted therapy for tumors.
Gao Y, Liu P, Shi R. · · 2020 · cited 108× · PMID 32724339 · DOI 10.3892/ol.2020.11685
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M, Chen X, Zhang H, Xia L, et al · · 2019 · cited 75× · PMID 31221221 · DOI 10.1186/s40880-019-0383-7

Verify or expand the search:

Other trials of Anlotinib

Trials testing the same drug.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Chia Tai Tianqing Pharmaceutical Group Co., Ltd. trials

Trials by the same sponsor.

NCT06990776 — A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects · Phase 2 · withdrawn
NCT06851442 — Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced o · Phase 1, PHASE2 · terminated
NCT06711991 — A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease · Phase 1 · completed
NCT06672276 — To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency · Phase 1 · completed
NCT06644417 — Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Tre · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02388919 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Last refreshed: 18 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02388919.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing